4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Current Leases data on file, last reported at $5.5 million in Q1 2026.

• Current Leases for Q1 2026 came in at $5.5 million, down 3.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (down 3.4% YoY), and the FY2025 annual result was $5.6 million, down 0.8% from the prior year.
• Current Leases declined to $5.5 million in Q1 2026 per FDMT's latest filing, from $5.6 million in the prior quarter.
• Over five years, Current Leases peaked at $5.7 million in Q2 2025 and troughed at $2.0 million in Q1 2022.
• A 5-year average of $4.0 million and a median of $3.2 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2026: Current Leases jumped 115.68% in 2022, then slipped 3.4% in 2026.
• A 5-year view of Current Leases shows it stood at $2.7 million in 2022, then climbed by 18.61% to $3.1 million in 2023, then jumped by 79.01% to $5.6 million in 2024, then decreased by 0.8% to $5.6 million in 2025, then decreased by 1.9% to $5.5 million in 2026.
• Business Quant data shows FDMT's Current Leases at $5.5 million in Q1 2026, $5.6 million in Q4 2025, and $5.7 million in Q3 2025.